Cargando…
Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment
On 30 January 2020, the World Health Organization (WHO) declared the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic a public health emergency of international concern. The viral outbreak led in turn to an exponential growth of coronavirus disease 2019 (COVID-19) cases, t...
Autores principales: | Taibe, Noha Samir, Kord, Maimona A., Badawy, Mohamed Ahmed, Shytaj, Iart Luca, Elhefnawi, Mahmoud M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597285/ https://www.ncbi.nlm.nih.gov/pubmed/36282077 http://dx.doi.org/10.1177/17534666221132736 |
Ejemplares similares
-
Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS
por: Savarino, Andrea, et al.
Publicado: (2015) -
A cure for AIDS: a matter of timing?
por: Shytaj, Iart Luca, et al.
Publicado: (2013) -
A scalable workflow to test “shock and kill” therapeutic approaches against the HIV-1 latent reservoir in blood cells ex vivo
por: Procopio, Francesco Andrea, et al.
Publicado: (2023) -
Progress and pitfalls of a year of drug repurposing screens against COVID-19()
por: Sourimant, Julien, et al.
Publicado: (2021) -
Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies
por: Mahmoud, Amal, et al.
Publicado: (2021)